YF-VAX®

Product Information

• Name: YF-VAX®
• Type: Yellow Fever Vaccine, Live Attenuated
• Form: Lyophilized powder for reconstitution
• Manufacturer: Sanofi Pasteur Limited

Indications and Clinical Use

• Indication:
  • Active immunization against yellow fever in persons 9 months of age or older.
  • Recommended for travelers to or living in areas where yellow fever is officially reported.
  • Required by law for entry to certain countries.
  • Recommended for laboratory personnel exposed to the virus.

Dosage and Administration

• Recommended Dose:
  • Primary Vaccination: Single 0.5 mL dose administered subcutaneously.
  • Booster Dose: Every 10 years for those at continuous risk.
• Administration:
  • Reconstitute with the provided diluent (0.9% Sodium Chloride Injection USP).
  • Administer subcutaneously in the deltoid region.
  • Use reconstituted vaccine within 60 minutes.

Contraindications

• Known hypersensitivity to any component of the vaccine, including egg proteins.
• Severe allergic reaction after previous administration of yellow fever vaccine.
• Individuals with immunodeficiency, thymic disorders, or who are on immunosuppressive therapies.
• Infants under 9 months of age.
• Pregnant women should avoid unless travel to endemic areas is unavoidable.

Warnings and Precautions

• General:
  • Evaluate the risk of yellow fever exposure versus vaccine-associated adverse events.
  • Syncope can occur; manage to prevent injury.
• Special Populations:
  • Pregnant Women: Vaccinate only if necessary; monitor infants born to vaccinated women.
  • Nursing Women: Use with caution; possible transmission through breast milk.
  • Immunocompromised Individuals: Generally contraindicated; assess risk versus benefit.
  • Older Adults (60+): Higher risk of serious adverse events; individual risk assessment recommended.
• Adverse Reactions:
  • Common: Injection site pain, redness, swelling, fever, headache, myalgia.
  • Rare: Anaphylaxis, yellow fever vaccine-associated viscerotropic and neurotropic disease.

Drug Interactions

• Vaccine-Drug Interactions: Avoid concurrent use with immunosuppressive treatments.
• Concomitant Vaccine Administration:
  • Can be administered with measles, mumps, rubella, hepatitis A, hepatitis B, meningococcal, and typhoid vaccines.
  • Separate sites and syringes required.

Storage and Stability

• Store at 2°C to 8°C. Do not freeze.
• Use reconstituted vaccine within 60 minutes.

Clinical Trials and Efficacy

• Immunogenicity:
  • High seroconversion rates (91%-100%) in various studies.
  • 99.3% seroconversion in adults 18 years and older.
• Safety:
  • Most adverse events are mild to moderate.
  • Serious adverse events are rare but include viscerotropic and neurotropic disease.